Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept versus belimumab with standard care for lupus nephritis
ChiCTR2400090264Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of telitacicept and belimumab in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Renal response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
telitaciceptbelimumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2400090264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090264.